E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Ear, nose and throat diseases [C09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001723 |
E.1.2 | Term | Allergic rhinitis |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this study is to describe the safety and pharmacokinetic of Olopatadine Hydrochloride Nasal Spray 0.6% administered twice daily in pediatric patients 2 to < 6 years of age. |
|
E.2.2 | Secondary objectives of the trial |
The purpose of this study is to describe the safety and pharmacokinetic of Olopatadine Hydrochloride Nasal Spray 0.6% administered twice daily in pediatric patients 2 to < 6 years of age. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. At least 2 years of age and less than 6 years of age on Day 1;
2. Parent/legal guardian was willing and able to give written informed consent and
a. provided this consent for the study;
3. Positive case history of allergic rhinitis symptoms and at least one documented positive skin test within the 5 years prior to Day 1;
4. Willing and able to make required study visits and able to follow instructions;
5. Absence of significant anatomic abnormalities, infection, bleeding, and mucosal ulcerations at Screening and prior to administration of test article at the Day 1 Visit;
6. Other protocol-specified inclusion criteria may apply.
|
|
E.4 | Principal exclusion criteria |
1. Chronic or intermittent use of any prescription or over-the-counter nasal spray during the study period;
2. Use of any form of olopatadine (e.g., PATANOL®, PATADAY™, PATANASE®) within 7 days of Day 1;
3. Currently or recent (within 14 days) use of any drugs/drug classes or combinations thereof that may prolong the QT interval;
4. History, diagnosis, or evidence of infection, syndrome, disease, abnormality, or malfunction that may interfere with the investigation, evaluation of study medication, or results of the study, as specified in the protocol;
5. Hypersensitivity to olopatadine, benzalkonium chloride, or any component of the test articles;
6. Other protocol-specified exclusion criteria may apply.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of Participants With Anatomic Nasal Exam Abnormalities [ Time Frame: Day 1
(Baseline) to Exit ]
The appearance in a participant of any of the following from Baseline: anatomic
abnormalities, evidence of infection, bleeding, and/or ulcerations of the mucosa |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Maximum plasma concentration (Cmax)
Time to attain Cmax from time of last dose (Tmax)
Area under the plasma concentration - time curve (AUC0-12) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Safety and Pharmacokinetics |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 15 |